Picture of CanaQuest Medical logo

CANQF CanaQuest Medical Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-30.64%
3m-55.98%
6m-75.06%
1yr-85.62%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w High-90.54%
50d MA-47.15%
200d MA-79.07%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 201931st Mar 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2019 / 2020

Blurred out image of CanaQuest Medical EPS forecast chart

Profile Summary

CanaQuest Medical Corp is a Canada-based clinical-stage, life sciences company. The Company is focused on the drug discovery and development of targeted therapeutics within the endocannabinoidome, including PPAR receptors. The Company is focused on treating neurological conditions, such as epilepsy, anxiety, depression, and post-traumatic stress disorder (PTSD). It has created a natural formulation derived from cannabidiol + proprietary API composition. The Company has a drug candidate, CQ-001, positioned for clinical trials targeting epilepsy. Its CQ-001 drug candidate combines cannabidiol (CBD) with essential fatty acids (Omega-3s). In addition, the Company is also focused on developing a nutraceutical version of the formulation, Mentanine, which is scheduled for clinical studies to investigate its potential applications across various indications, paving the way for future clinical trials.

Directors

    Last Annual
    March 31st, 2018
    Last Interim
    March 31st, 2018
    Incorporated
    October 7th, 2008
    Public Since
    October 27th, 2014
    Sector
    Pharmaceuticals
    Industry
    Healthcare
    Exchange
    us flag iconPink Sheets on Nasdaq
    Shares in Issue
    21,411,377

    CANQF Share Price Performance

    Upcoming Events for CANQF

    Similar to CANQF

    Picture of Acusphere logo

    Acusphere

    us flag iconPink Sheets on Nasdaq

    Picture of Adorbs logo

    Adorbs

    us flag iconPink Sheets on Nasdaq

    Picture of Agentix logo

    Agentix

    us flag iconPink Sheets on Nasdaq

    Picture of Agrios Global Holdings logo

    Agrios Global Holdings

    us flag iconPink Sheets on Nasdaq

    Picture of Aida Pharmaceuticals logo

    Aida Pharmaceuticals

    us flag iconPink Sheets on Nasdaq

    FAQ